CD19 and infection: Unlike in the case of CD19 CAR T cells whereby complete elimination of both normal and cancerous B cells is clinically benign, in stark contrast, prolonged myeloablation as a result of CAR T cells targeting myeloid antigens shared with normal myeloid progenitors is ultimately fatal due to neutropenic infections and bleeding complications.